Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$1.94
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.94
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$273.12M
Enterprise Value$264.15M
Total Cash (Recent Filing)$51.85M
Total Debt (Recent Filing)$13.55M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding64,872,980
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit1.60
Enterprise Value/Ebitda-5.70
Forecast
1Y Price Target
$4.50Price Target Upside131.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$206.33M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained near-80% gross margins reflect strong product-level economics and pricing power for proprietary implants and disposables. High margins provide structural buffer to fund commercialization and tolerate investment while management narrows operating losses and scales recurring per-procedure revenue over the next several quarters.
Product Portfolio Expands TAMIntroducing multiple complementary systems and upcoming Q3 launches materially increases addressable market and cross-sell opportunities. A larger TAM supports durable long-term revenue potential as surgeon adoption and case penetration grow, lowering concentration risk tied to the core Lapiplasty product over 2–6 months and beyond.
Surgeon Adoption & Procedure MomentumA growing active surgeon base and measurable pull-through to new systems indicate durable commercial traction. Consistent mid-single-digit procedure volume growth suggests utilization-driven recurring product demand, which supports predictable consumable revenue per case as training and clinical adoption deepen over coming quarters.
Bears Say
Persistent Negative Cash FlowContinued negative operating and free cash flow forces reliance on existing cash balances and potentially external financing, limiting strategic flexibility. Even with reduced burn in 2025/TTM, ongoing outflows constrain investments and increase execution risk until the company achieves sustained internal cash generation.
Ongoing Operating LossesProjected adjusted EBITDA losses through 2026 imply the business has not yet converted high product margins into profitability. Persistent operating deficits erode equity and restrict reinvestment capacity, keeping returns negative and making consistent progress toward break-even a key medium-term execution risk.
ASP / Mix Headwind From Lower‑priced ProductsExpanding into lower-priced minimally invasive offerings dilutes average selling price and depresses near-term revenue despite higher procedure counts. This structural mix shift can mask volume gains and delay revenue recovery, making top-line improvement contingent on lapping mix effects later in 2026.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $273.12M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Aug 11, 2026 which is in 38 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.028.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.3.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,872,980 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went up 4.687%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (131.96% Upside)
$4.50 (131.96% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-69.50%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
TMCI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: commercial execution and product momentum are clear positives (rapid adoption of new systems, expanding TAM, high gross margins, improved cash balance and reduced cash burn expectations), but near-term financials remain challenged (Q1 revenue down 10%, larger net and EBITDA losses, and ASP/mix headwinds). Management is taking a conservative posture—reaffirming guidance while highlighting the path to lapping mix headwinds in the back half of 2026 and expecting revenue growth to return in Q4. Overall, operational improvements and promising adoption trends offset but do not yet fully overcome the near-term revenue and profitability headwinds, leaving the situation balanced between encouraging commercial traction and ongoing financial pressure.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$4.50
▲(131.96% Upside)
Technical Analysis
Ownership Overview
28.33% Insiders
6.08% Mutual Funds
20.48% Other Institutional Investors
40.58% Public Companies and
Individual Investors







